CBD Oil Did Not Improve Psoriasis Severity But Temporarily Relieved Itch and Sleep

In a 28-patient RCT, oral CBD oil 60 mg/day did not significantly improve PASI (Psoriasis Area and Severity Index) scores versus placebo. However, itch scores were notably reduced by Week 8, and sleep onset latency decreased by Week 6, though this sleep effect was not sustained. Adverse events were mild to moderate and similar across groups.

Randomized, double-blind, placebo-controlled trial of 28 chronic plaque psoriasis patients receiving oral CBD oil 60 mg/day or placebo, with PASI as primary outcome and quality of life, itch, and sleep as secondary outcomes.

Despite widespread consumer interest in CBD for skin conditions, this is one of the first rigorous placebo-controlled trials. The negative primary outcome is important information, though the itch and sleep benefits suggest potential symptom-specific effects worth investigating further.

The disconnect between preclinical promise and clinical reality is a common theme in CBD research. The 60 mg dose may have been too low, and oral administration may not deliver sufficient concentrations to the skin. Topical CBD formulations might perform differently.

Very small sample (28 patients). Low CBD dose (60 mg/day). Short duration. Oral route may not optimize skin delivery. Race and disease severity may limit generalizability.